| INCY |
Report |
Total net revenue |
BEAT |
pred ~$1.43B vs. cons $1.40B |
MEDIUM |
| INCY |
Report |
Non-GAAP diluted EPS |
BEAT |
pred ~$1.96 vs. cons $1.85 |
MEDIUM |
| INCY |
Report |
Jakafi net product revenue |
BEAT |
pred ~$815M vs. cons $796.5M |
MEDIUM |
| INCY |
Guide |
FY2026 total net sales guide |
BETTER |
guide raised to ~$4.85-5.00B vs. cons ~$4.90B (FY2026); current range $4.77-4.94B |
LOW |
| INCY |
Guide |
FY2026 Heme/Onc portfolio guide |
BETTER |
guide raised to ~$860-940M vs. cons ~$865M (FY2026); current $800-880M |
MEDIUM |
| INCY |
Guide |
Opzelura Q2 net product revenue (vs. aggressive Street bar) |
LOWER |
pred ~$165M vs. cons $214.7M (Q2 2026) |
MEDIUM |
| INCY |
Guide |
Jakafi XR launch / mutCALR (989) + povorcitinib HS pipeline commentary |
UNKNOWN |
pred XR 10-30% Jakafi capture by 2029 vs. cons no explicit number (2026-2029); catalyst-dependent |
LOW |
| INCY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| INCY |
Return |
5-day cumulative residual |
-4.5% (FADE) |
Stock is priced for perfection: +73% YoY and +29% in the 7 weeks into the print, at 52-week highs, so a beat-and-modest-raise is already discounted. Even a clean top-line/EPS beat likely triggers a 'sell-the-news' fade (echoing prior muted/negative post-prints). Out-period math is a headwind: the ~$1.25B Vega upfront hits Q3 R&D and rising pipeline spend pressures 2H/2027 earnings, so implicit forward estimates get trimmed even after a Q2 beat; an aggressive Opzelura Street bar ($214.7M) also risks a visible line miss. Absent de-risking data on 989/KRAS/povo, momentum fades over the week. |
LOW |